The Antioxidant N-Acetylcysteine Prevents HIF-1 Stabilization under Hypoxia In Vitro but Does Not Affect Tumorigenesis in Multiple Breast Cancer Models In Vivo

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Sceneay, Jaclyn ^a,b,c   Liu, Mira C P ^a   Chen, Anna ^a,b   Wong, Christina S F ^c   Bowtell, David D L ^a,b   Möller, Andreas ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CD31 ANTIGEN; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; TUMOR VASCULARIZATION;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CARCINOGENESIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLUTATHIONE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROTEIN STABILITY; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 84879262343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066388     Document Type: Article

References (66)

1. Semenza GL, (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33: 207-214.
2. Lu X, Kang Y, (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16: 5928-5935.
3. Harris AL, (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
4. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
5. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, et al. (2009) Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 5: e1000394.
6. Wilson WR, Hay MP, (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
7. Moeller BJ, Richardson RA, Dewhirst MW, (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26: 241-248.
8. Rohwer N, Cramer T, (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14: 191-201.
9. Semenza GL, (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578.
10. Wang GL, Jiang BH, Rue EA, Semenza GL, (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514.
11. Jiang BH, Semenza GL, Bauer C, Marti HH, (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-1180.
12. Huang LE, Gu J, Schau M, Bunn HF, (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95: 7987-7992.
13. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L, (1999) Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 274: 6519-6525.
14. Salceda S, Caro J, (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647.
15. Pugh CW, Ratcliffe PJ, (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677-684.
16. Tian H, McKnight SL, Russell DW, (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82.
17. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, et al. (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260-2268.
18. Semenza GL, (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
19. Majmundar AJ, Wong WJ, Simon MC, (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309.
20. Bruick RK, McKnight SL, (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
21. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
22. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, et al. (1999) Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 103: 691-696.
23. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
24. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
25. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
26. Lee K, Qian DZ, Rey S, Wei H, Liu JO, et al. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 106: 2353-2358.
27. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, et al. (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66: 8814-8821.
28. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
29. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127.
30. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, et al. (2005) Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 65: 5325-5336.
31. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z, (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441.
32. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, et al. (2011) Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 17: 5123-5131.
33. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, et al. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238.
34. Brok J, Buckley N, Gluud C (2006) Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev: CD003328.
35. Millea PJ, (2009) N-acetylcysteine: multiple clinical applications. Am Fam Physician 80: 265-269.
36. Agarwal A, Munoz-Najar U, Klueh U, Shih SC, Claffey KP, (2004) N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol 164: 1683-1696.
37. Albini A, Morini M, D'Agostini F, Ferrari N, Campelli F, et al. (2001) Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 61: 8171-8178.
38. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, et al. (1994) Clinical development plan: N-Acetyl-l-cysteine. J Cell Biochem Suppl 20: 63-73.
39. De Flora S, D'Agostini F, Masiello L, Giunciuglio D, Albini A, (1996) Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer 67: 842-848.
40. D'Agostini F, Bagnasco M, Giunciuglio D, Albini A, De Flora S, (1998) Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol 13: 217-224.
41. Aitio ML, (2006) N-acetylcysteine - passe-partout or much ado about nothing? Br J Clin Pharmacol 61: 5-15.
42. Calvani M, Comito G, Giannoni E, Chiarugi P, (2012) Time-dependent stabilization of hypoxia inducible factor-1alpha by different intracellular sources of reactive oxygen species. PLoS One 7: e38388.
43. Albini A, D'Agostini F, Giunciuglio D, Paglieri I, Balansky R, et al. (1995) Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 61: 121-129.
44. Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, et al. (2012) Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis.
45. Wong CS, Sceneay J, House CM, Halse HM, Liu MC, et al. (2012) Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. Cancer Res 72: 1694-1704.
46. Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, et al. (2012) Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+ Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche. Cancer Research.
47. Casey AE, Laster WR Jr, Ross GL, (1951) Sustained enhanced growth of carcinoma EO771 in C57 black mice. Proc Soc Exp Biol Med 77: 358-362.
48. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17: 163-170.
49. Moller A, House CM, Wong CS, Scanlon DB, Liu MC, et al. (2009) Inhibition of Siah ubiquitin ligase function. Oncogene 28: 289-296.
50. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, et al. (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med.
51. Young RJ, Moller A, (2010) Immunohistochemical detection of tumour hypoxia. Methods Mol Biol 611: 151-159.
52. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J, (2010) ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12: R56.
53. Morgan LR, Donley PJ, Harrison EF, Hunter HL, (1982) Protective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphorine without interference with anticancer activity. Eur J Cancer Clin Oncol 18: 113-114.
54. Pastorino U, Chiesa G, Infante M, Soresi E, Clerici M, et al. (1991) Safety of high-dose vitamin A. Randomized trial on lung cancer chemoprevention. Oncology 48: 131-137.
55. Zafarullah M, Li WQ, Sylvester J, Ahmad M, (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60: 6-20.
56. Allegra L, Dal Sasso M, Bovio C, Massoni C, Fonti E, et al. (2002) Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneimittelforschung 52: 669-676.
57. Heller AR, Groth G, Heller SC, Breitkreutz R, Nebe T, et al. (2001) N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. Crit Care Med 29: 272-276.
58. Nathan C, Shiloh MU, (2000) Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A 97: 8841-8848.
59. Davreux CJ, Soric I, Nathens AB, Watson RW, McGilvray ID, et al. (1997) N-acetyl cysteine attenuates acute lung injury in the rat. Shock 8: 432-438.
60. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, et al. (2003) Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 81: 664-673.
61. Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, et al. (2003) N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplant 32: 349-354.
62. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H, (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977-986.
63. Loehrer PJ Sr, Birch R, Kramer BS, Greco FA, Einhorn LH, (1986) Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70: 919-920.
64. Maasilta P, Holsti LR, Blomqvist P, Kivisaari L, Mattson K, (1992) N-acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: a feasibility study. Radiother Oncol 25: 192-195.
65. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, et al. (2001) SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166: 1311-1315.
66. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556.